RxDoctor Payments Data

Mark Tetz, MD

Family Medicine · Visalia, CANPI 1891779138

Payments from drug & device makers

$12,109in general payments, 2019–2025

Across 604 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$1K
  • Amgen$714
  • Merck$595
  • plus $5K from 51 others

What the payments were for

  • Food & beverage$11,91498%
  • Education$1361%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)100$1,961
AstraZeneca69$1,354
Boehringer Ingelheim70$1,168
Lilly USA, LLC50$1,002
Amgen31$714
Merck30$595
Novo Nordisk44$524
Amarin Pharma, Inc.16$394
Pfizer21$359
Biohaven Pharmaceutical Holding Company Ltd.14$332
Bayer14$330
Axsome Therapeutics, Inc.5$303
Biohaven Pharmaceuticals, Inc.6$230
GSK9$227
Takeda Pharmaceuticals U.S.A., Inc.10$195
Idorsia Pharmaceuticals US Inc11$172
Dynavax Technologies Corporation3$158
Eisai Inc.10$153
Otsuka America Pharmaceutical, Inc.7$142
Astellas Pharma US Inc4$141
Mannkind Corporation5$132
Mylan Specialty L.p.5$110
Sanofi1$108
Sanofi-aventis U.S. LLC5$103
Arbor Pharmaceuticals, Inc.5$79
Daiichi Sankyo Inc.4$78
Sumitomo Pharma America, Inc.4$73
Kowa Pharmaceuticals America, Inc.3$72
Ultragenyx Pharmaceutical Inc.3$64
Antares Pharma, Inc.3$58
Verity Pharmaceuticals Inc.3$51
Abbott3$51
Dexcom, Inc.3$50
Abiomed2$49
Phathom Pharmaceuticals, Inc.2$38
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$37
Optos, Inc.2$36
Supernus Pharmaceuticals, Inc.2$36
Nalu Medical, Inc.1$35
Medtronic1$34
Seqirus USA Inc2$32
Cranial Technologies, Inc2$32
Zyla Life Sciences, Inc.2$31
Ironwood Pharmaceuticals, Inc2$28
EUSA Pharma (US) LLC1$25
Genentech USA, Inc.1$22
Jazz Pharmaceuticals Inc.1$22
Esperion Therapeutics, Inc.1$21
Vertex1$20
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$19
Aimmune Therapeutics, Inc.1$17
Viatris Specialty LLC1$17
Sanofi Pasteur Inc.1$17
Johnson & Johnson1$16
Xeris Pharmaceuticals, Inc.1$16
Paratek Pharmaceuticals, Inc.1$13
Shire North American Group Inc1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,109 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$383,602
Medicare patients
452
Services billed
5,808

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide127$133,632
JardianceEmpagliflozin116$116,222
FarxigaDapagliflozin Propanediol103$104,440
MounjaroTirzepatide79$82,986
Synjardy XrEmpagliflozin/Metformin Hcl57$75,316
TrulicityDulaglutide47$62,020
Soliqua 100-33Insulin Glargine/Lixisenatide51$50,583
Xigduo XrDapaglifloz Propaned/Metformin43$48,781
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$43,190
EliquisApixaban41$42,122
MyrbetriqMirabegron43$38,683
OxycontinOxycodone Hcl12$30,205
LinzessLinaclotide23$26,547
BelsomraSuvorexant42$24,579
TrintellixVortioxetine Hydrobromide19$21,784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat$1,168$196,768184 claims
Novo NordiskOzempic, Rybelsus$524$148,910143 claims
Lilly USA, LLCMounjaro, Trulicity$1,002$145,006126 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,354$116,050116 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$227$66,53585 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$103$50,58351 claims
PfizerEliquis$359$42,12241 claims
Astellas Pharma US IncMyrbetriq$141$38,68343 claims
AbbVieLinzess, Synthroid$1,961$29,89053 claims
MerckBelsomra, Dulera$595$29,43055 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$195$21,78419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Visalia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →